Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Melinta Therapeutics, LLC
Melinta Therapeutics Announces the Appointment of Sunitha Lakshminarayanan, as Chief Technology Officer
September 05, 2024
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces the Appointment of Fabrizio Tondolo, MD, as Vice President of Medical Affairs
August 06, 2024
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces Publication of the Outcomes by Candida Species from the ReSTORE Phase 3 trial and Recently Approved Rezafungin CLSI Breakpoints for Candida glabrata and Candida auris
May 23, 2024
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics & Cidara Therapeutics Announce Publication of Pooled Data from Phase 3 Pivotal ReSTORE Trial & Phase 2 STRIVE Trial of REZZAYO® (rezafungin for injection) for the Treatment of Candidemia & Invasive Candidiasis in The Lancet ID
December 05, 2023
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces Presentations of New Data on Infectious Disease Portfolio at IDWeek 2023
October 11, 2023
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces Commercial Availability of REZZAYO™ (rezafungin for injection)
July 31, 2023
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens
July 10, 2023
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada
May 15, 2023
From
Melinta Therapeutics, LLC
Via
Business Wire
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis
March 22, 2023
From
Melinta Therapeutics, LLC
Via
Business Wire
Tickers
CDTX
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
January 25, 2023
From
Melinta Therapeutics, LLC
Via
Business Wire
Tickers
CDTX
Melinta Therapeutics & OptimizeRx Announce 2022 Innovate4Outcomes Event
November 30, 2022
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces Presentation of New Data on Infectious Disease Portfolio at IDWeek 2022
October 18, 2022
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.
July 27, 2022
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Acquires U.S. Rights to TOPROL-XL® (metoprolol succinate) from New American Therapeutics
April 06, 2022
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces Appointment of Peter Piliero as Vice President of Medical Affairs
March 14, 2022
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio
January 06, 2022
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development
October 25, 2021
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy
July 06, 2021
From
Melinta Therapeutics, LLC
Via
Business Wire
Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer
June 29, 2021
From
Melinta Therapeutics, LLC
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.